Showing 3081-3090 of 4130 results for "".
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://practicaldermatology.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://practicaldermatology.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Analysis: Long Waits for Pediatric Dermatology Appointments Across UShttps://practicaldermatology.com/news/study-finds-long-waits-for-pediatric-dermatology-appointments-across-us/2486313/Children seeking dermatologic care in the US face long waits regardless of where they are referred, according to a research letter published online in JAMA Dermatology. Using a mystery caller design, investigators as
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- Review: Dermoscopic Patterns May Improve Differentiation of Acral Melanoma and Nevihttps://practicaldermatology.com/news/review-dermoscopic-patterns-may-improve-differentiation-of-acral-melanoma-and-nevi/2486062/A systematic review and meta-analysis in JAMA Dermatology provides updated evidence on dermoscopic features that differentiate acral lentiginous melanoma (ALM) from benign acral nevi. Investigators searched Embase, P
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac